CalciMedica, Inc. stock is up 83.76% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 November’s closed higher than October. 100% of analysts rate it a buy.
CalciMedica, Inc. focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials. GB-401, an implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma.